BioPharmSignal logoBioPharmSignal

Biotech News

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

RxSight (RXST)RxSightCompany update

ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight’s common stock and inducement restricted stock units (RSUs) covering a total of

Related news

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RXSTRxSight2026-07-15 20:15 EST

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

DCTHDelcath Systems2026-07-16 20:01 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PLSEPulse Biosciences2026-07-15 20:05 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-06-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

STIMNeuronetics2026-07-31 21:00 EST

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OMOutset Medical2026-07-02 20:05 EST

Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

IARTIntegra LifeSciences2026-06-15 12:30 EST

Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference

IRIXIRIDEX2026-06-09 20:05 EST

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

View all latest news

RxSight

Adjustable Cataract Lenses RxSight is an ophthalmic medical-device company focused on customized vision after cataract surgery. Light Adjustable Lens System The system combines an implantable Light Adjustable Lens with a Light Delivery Device. After surgery, physicians use ultraviolet light treatments to modify the lens and refine the...

Recent company news

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RXSTRxSight2026-07-26 20:00 EST

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

RXSTRxSight2026-07-15 20:15 EST

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RXSTRxSight2026-07-06 20:16 EST

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

Stock data

Close
6.08 USD
Market cap
204.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States